SUMMARY A quantitative mouse calvarial bone resorption assay was employed to investigate the effects of the mast cell products, heparin and histamine, and of salmon calcitonin. 'Amorphous' heparin, containing a range of molecular weight fractions, inhibited resorption by 15-20% at concentrations of 0-75-5.0 mg/ml. A 'defined' heparin species of mol.wt 13 500 inhibited resorption by 14-28% at 10-5-10-i mol/l. Histamine inhibited resorption by 19-55% at 10-3_10-2 mol/l. It is proposed that heparin and histamine depress coupled bone resorption and formation and may lead to net loss of bone. Salmon calcitonin inhibited resorption at concentrations as low as 10 pg/ml. 'Amorphous' (but not 'defined') heparin blunted calcitonin induced inhibition of bone resorption and may derepress osteoclasts.
sole source of endogenous heparin2 and the major source of tissue histamine. 3 Chronic administration of exogenous heparin to humans, when used in the treatment of ischaemic heart disease, causes a dose related osteoporosis,>8 and de Swiet et al have recently confirmed that heparin promotes significant bone loss in women treated for thromboembolic disease in pregnancy. 9 The mechanism of heparin induced bone loss is uncertain. There is some evidence that heparin may stimulate the resorption of devitalised bone particles implanted subcutaneously into rats,'(' but the weight of present evidence indicates that the effect of heparin is primarily antianabolic rather than catabolic. It inhibited linear growth and new bone formation in cultured neonatal mouse bone'1 and fracture healing in dogs and rabbits. 12 Heparin qualitatively inhibited the remodelling of cultured human trabecular bone fragments. i3 The antiproliferative effect of heparin on bone is compatible with previous reports that it inhibits the division of a number of cell types, but smooth muscle cells most consistently.'4t6 Preliminary studies have shown that heparin has also impaired the division of cultured isolated human trabecular bone cells. 17 Histamine binding sites have been recently de- Accepted for publication 5 inhibition of bone resorption was recorded at 0X75 mg/ml (3-75-7X5x10-5 mol/l) and 5 mg/ml (2-5-5x10-4 mol/l). This represents inhibition of 18% (p<005) and 20% (mean of two experiments: p<0-01 and <0.02) respectively. A 15% inhibition was also noted with heparin 1 mg/ml but this did not reach significance. No difference was observed with heparin 10 mg/ml (0.5-1 x 1(-3 mol/l).
Defined heparin (Table 2) No effects on bone resorption were found at 10-7_10-6 mol/l. At 10-5 mol/l (0-135 mg/ml) a 14% inhibition of bone resorption was noted (p<005).
At 10-4 mol/l (1.35 mg/ml) a 28% inhibition was observed (p<0001). It is apparent that defined heparin is a more potent inhibitor of bone resorption than amorphous heparin on a weight basis. The data were derivcd from sevcn separate expcriments on quintuplct or scxtuplct specimens. (p<(0.00l) and 34% (p<(0.01) respectively (Fig. la) . The difference in inhibition under these two conditions was not significant and no modulatory effect of heparin 0(5 mg/ml could therefore be shown.
Calcitonin 1 [tg/ml alone and calcitonin 1 [tg/ml+ heparin 0(75 mg/ml inhibited resorption 56°/ (p<0-001) and 62% (p<0)01) respectively (Fig. lb) . The difference was insignificant.
(alcitonin 1 Ftg/ml alone aind calcitonin 1 Fg/ml+ heparin 1 mg/ml inlibited resorptiol 59%°(p<0-0()l aind 51%o (p<0)l (1) respectively. This blunting of calcitonin itiduced inhibition in the presence ot heparin 1 mg/mIl w.ls significant at p<0(05 (Fig. lc) . (p<0001) and 42% (p<0.001) respectively. This inhibition of calcitonin induced inhibition of bone resorption was significant at p<0O001 (Fig. ld) .
Defined heparin (Table 5 ) Salmon calcitonin 100 pg/ml inhibited bone resorption 57% (p<0-001) (Table 4) . When bones were incubated in salmon calcitonin 100 pg/ml in the presence of defined heparin 10-6_10-4 molI no modulation of calcitonin induced inhibition was found.
Discussion
The rheumatoid bone erosion is characterised by active osteoclastic bone resorption of juxta-articular bone. Less attention is paid, however, to the coupled process of new bone formation and attempted repair which occurs on the opposite side of a bone surface undergoing resorption. ' 
